Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), a US-based company that deals with RNA-targeted therapy, announced on Monday that it has signed a license agreement with Japan-based Otsuka Pharmaceutical Co., Ltd. (Otsuka).

Under the contract, Otsuka is to receive exclusive rights in Europe to commercialise donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE). Ionis is to maintain responsibility for the non-clinical and clinical development of donidalorsen, while Otsuka will be responsible for European regulatory filings and commercialisation. Ionis is to receive a USD65m upfront payment and milestone payments based on achievement of regulatory and sales targets. Ionis is also qualified to receive tiered royalties ranging from 20% to 30% (based on aggregate annual net sales).

If donidalorsen is approved, Ionis plans to independently introduce the product in the US under company's strategy to deliver a steady flow of wholly owned medicines to patients.

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE